Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

K. McGlinchey · SciRah

Researcher profile · Semantic Scholar

K. McGlinchey

Share profile

K. McGlinchey — researcher profile on SciRah

h-index: 20
Works: 44
Citations: 1,534

Most-cited papers

Targeting CD73 in the tumor microenvironment with MEDI9447
Carl M. Hay, Erin Sult, Qi-Hui Huang, K. Mulgrew +14 more
2016Oncoimmunology260 citations Open access
Semantic Scholar
Dasatinib (BMS-354825) Pharmacokinetics and Pharmacodynamic Biomarkers in Animal Models Predict Optimal Clinical Exposure
F. Luo, Zheng Yang, Amy Camuso, Richard A. Smykla +10 more
2006Clinical Cancer Research151 citations
Semantic Scholar
Anti–PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC
Eric Tu, K. McGlinchey, Ji-Xin Wang, Philip Martin +13 more
2022JCI Insight110 citations Open access
Semantic Scholar
Antibody-Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies.
J. Rios-Doria, Jay Harper, R. Rothstein, Leslie K Wetzel +16 more
2017Cancer Research109 citations Open access
Semantic Scholar
Preclinical efficacy spectrum and pharmacokinetics of ixabepilone
F. Lee, Richard A. Smykla, Kathy A. Johnston, Krista Menard +6 more
2008Cancer Chemotherapy and Pharmacology105 citations Open access
Semantic Scholar
AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein–specific TH1 response with a diverse TCR repertoire
Phillip A. Swanson, M. Padilla, W. Hoyland, K. McGlinchey +65 more
2021Science Translational Medicine88 citations Open access
Semantic Scholar
Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft
F. Luo, Zheng Yang, H. Dong, Amy Camuso +10 more
2005Cancer Chemotherapy and Pharmacology88 citations
Semantic Scholar
Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels
R. Wild, Krista Fager, C. Flefleh, D. Kan +6 more
2006Molecular Cancer Therapeutics67 citations Open access
Semantic Scholar
Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy.
N. Durham, K. Mulgrew, K. McGlinchey, N. Monks +5 more
2017Molecular Therapy64 citations Open access
Semantic Scholar
Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL™), a multi-targeted kinase inhibitor
F. Luo, Y. Barrett, Zheng Yang, Amy Camuso +9 more
2008Cancer Chemotherapy and Pharmacology51 citations Open access
Semantic Scholar
A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist
R. Leyland, A. Watkins, K. Mulgrew, Nicholas Holoweckyj +18 more
2017Clinical Cancer Research46 citations Open access
Semantic Scholar
Antitumor activity of AZD0754, a dnTGFβRII-armored, STEAP2-targeted CAR-T cell therapy, in prostate cancer
Peter Zanvit, D. van Dyk, Christine Fazenbaker, K. McGlinchey +25 more
2023Journal of Clinical Investigation44 citations Open access
Semantic Scholar
BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad-spectrum antitumor activities in vitro and in vivo
F. Lee, L. Lombardo, Amy Camuso, S. Castaneda +15 more
200544 citations
Semantic Scholar
GITR ligand fusion protein agonist enhances the tumor antigen–specific CD8 T-cell response and leads to long-lasting memory
N. Durham, Nicholas Holoweckyj, R. MacGill, K. McGlinchey +2 more
2017Journal of Immunotherapy for Cancer37 citations Open access
Semantic Scholar
Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
M. Oberst, C. Augé, Chad Morris, S. Kentner +18 more
2018Molecular Cancer Therapeutics36 citations Open access
Semantic Scholar
Preclinical efficacy evaluation of ixabepilone (BMS-247550) in combination with cetuximab or capecitabine in human colon and lung carcinoma xenografts.
F. Lee, Amy Camuso, Stephen Castenada, C. Flefleh +5 more
2006Journal of Clinical Oncology35 citations
Semantic Scholar
Prediction of Active Drug Plasma Concentrations Achieved in Cancer Patients by Pharmacodynamic Biomarkers Identified from the Geo Human Colon Carcinoma Xenograft Model
F. Luo, Zheng Yang, Hui-Jing Dong, Amy Camuso +10 more
2005Clinical Cancer Research27 citations Open access
Semantic Scholar
Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer
D. Schofield, Jennifer L. Percival-Alwyn, Mateusz Rytelewski, J. Hood +17 more
2021mAbs24 citations Open access
Semantic Scholar
Design, synthesis, and structure-activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitors.
L. Lombardo, Amy Camuso, J. Clark, Krista Fager +17 more
2005Bioorganic & Medicinal Chemistry Letters21 citations Open access
Semantic Scholar
Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor Immunity
J. Harper, S. Burke, J. Travers, N. Rath +15 more
2021Molecular Cancer Therapeutics20 citations Open access
Semantic Scholar
Dasatinib (BMS-354825) Overcomes Multiple Mechanisms of Imatinib Resistance in Chronic Myeloid Leukemia (CML).
F. Lee, Mei-Li Wen, R. Bhide, Amy Camuso +11 more
200520 citations
Semantic Scholar
T-cell mediated immunity after AZD1222 vaccination: A polyfunctional spike-specific Th1 response with a diverse TCR repertoire
Phillip A. Swanson, M. Padilla, W. Hoyland, K. McGlinchey +61 more
2021medRxiv18 citations Open access
Semantic Scholar
BMS-354825, a Dual SRC/ABL Kinase Inhibitor, Displays Potent Anti-Tumor Activity in a Model of Intracranial CML Growth.
R. Wild, S. Castaneda, C. Flefleh, Krista Fager +11 more
200415 citations
Semantic Scholar
Safety and tolerability of MEDI0562, an OX40 agonist monoclonal antibody, in combination with durvalumab or tremelimumab in adult patients with advanced solid tumors.
J. Goldman, S. Piha-Paul, B. Curti, K. Pedersen +13 more
2022Clinical Cancer Research12 citations Open access
Semantic Scholar
BMS-871: a novel orally active pan-Notch inhibitor as an anticancer agent.
Weifang Shan, A. Balog, C. Quesnelle, P. Gill +27 more
2015Bioorganic & Medicinal Chemistry Letters11 citations Open access
Semantic Scholar
Preclinical pharmacology of epothilone-folate conjugate BMS-753493, a tumor-targeting agent selected for clinical development
K. Covello, C. Flefleh, Krista Menard, Amy Wiebesiek +10 more
200811 citations
Semantic Scholar
Abstract 285: MEDI9447: enhancing anti-tumor immunity by targeting CD73 In the tumor microenvironment
Carl M. Hay, Erin Sult, Qi-Hui Huang, S. Hammond +8 more
20159 citations
Semantic Scholar
Quiescent Chronic Myelogenous Leukemia (CML) Cells Are Resistant to BCR-ABL Inhibitors but Preferentially Sensitive to BMS-214662, a Farnesyltransferase Inhibitor (FTI) with Unique Quiescent-Cell Selective Cytotoxicity.
F. Lee, Mei-Li Wen, Amy Camuso, Stephen Castenada +10 more
20055 citations
Semantic Scholar
A novel murine GITR ligand fusion protein induces antitumor activity as a monotherapy, which is further enhanced in combination with an OX40 agonist
R. Leyland, A. Watkins, K. Mulgrew, Nicholas Holoweckyj +21 more
20163 citations
Semantic Scholar
Pharmacokinetics- and Pharmacodynamics-Guided Optimization of the Dose and Treatment Schedule for the Dual SRC/ABL Inhibitor BMS-354825.
F. Luo, Zheng Yang, Amy Camuso, Richard A. Smykla +12 more
20043 citations
Semantic Scholar
Abstract 1435: Utilization of CLDN18.2 syngeneic mouse models to study chimeric antigen receptor T cells in immunocompetent mice
S. Breen, Rosa A Carrasco, K. McGlinchey, Brianna Janocha +8 more
2024Cancer Research1 citations
Semantic Scholar
Abstract LB085: Antitumor activity of AZD0754, a dnTGFbRII armored STEAP2 targeted CAR-T therapy, in preclinical models of prostate cancer
D. van Dyk, P. Zanvit, Christine Fazenbaker, K. McGlinchey +12 more
2023Cancer Research1 citations
Semantic Scholar
Abstract 5544: Newcastle Disease Virus in human derived tumors: Understanding immune recruitment and activation via virally delivered IL-12
N. Durham, K. McGlinchey, S. Burke, T. Creasy +11 more
2020Immunology1 citations
Semantic Scholar
Abstract 911: Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR mutant NSCLC
Eric Tu, K. McGlinchey, Yelena Lazdun, James H Kurasawa +5 more
2020Immunology1 citations
Semantic Scholar
Abstract 2267: MEDI5083, a novel CD40L-Fc fusion protein, activates the CD40 pathway on antigen-presenting cells and promotes robust anti-tumor immune responses in both hot and cold murine tumor models
D. Malhotra, S. Turman, K. McGlinchey, Ya-Ya Wang +1 more
2020Immunology1 citations
Semantic Scholar
5-1-2018 Potent Immune Modulation by MEDI 6383 , an Engineered Human OX 40 Ligand IgG 4 P Fc Fusion Protein
M. Oberst, C. Augé, Chad Morris, S. Kentner +20 more
20191 citations
Semantic Scholar
Human OX40 ligand fusion protein (MEDI6383) as a potent OX40 agonist and immuno-modulator in vitro and in vivo.
S. Hammond, Chad Morris, C. Augé, Qun Du +10 more
20151 citations
Semantic Scholar
325 Armored STEAP2 CAR-T (AZD0754) alone and in combination with enzalutamide demonstrates anti-tumor activity across a range of STEAP2 expressing prostate cancer PDX models
Peter Zanvit, K. McGlinchey, Christine Fazenbaker, Weichuan Luo +5 more
2023Regular and Young Investigator Award Abstracts0 citations Open access
Semantic Scholar
Abstract 1534: MEDI5083, a novel CD40L-Fc fusion protein, activates the CD40 pathway on antigen presenting cells and promotes a robust anti-tumor immune response in a B16F10 murine tumor model
S. Turman, K. McGlinchey, Ya-Ya Wang, D. Malhotra +2 more
2019Immunology0 citations
Semantic Scholar
Abstract 4596: Antibody-drug conjugates bearing pyrrolobenzodiazepine or tubulysin payloads alter the tumor immune microenvironment and synergize with multiple immunotherapies
J. Rios-Doria, Jay Harper, R. Rothstein, Leslie K Wetzel +16 more
20170 citations
Semantic Scholar
Abstract 4275: Agonist OX40 ligand fusion proteins induce effector T cell proliferation, block regulatory T cell function and can combine with immune checkpoint inhibitors to promote antitumor immunity in preclinical models
K. McGlinchey, K. Mulgrew, Chad Morris, C. Augé +10 more
20150 citations
Semantic Scholar
Dasatinib Once-Daily Dose Regimen Provides Robust Anti-Leukemic Activity While Avoiding Suppression of T Cell Activation.
G. Schieven, Rosemary F Zhang, Sidney Pitt, K. McGlinchey +7 more
20090 citations
Semantic Scholar
ARMORED STEAP2 CAR-T (AZD0754) ALONE AND IN COMBINATION WITH ENZALUTAMIDE DEMONSTRATES ANTI-TUMOR ACTIVITY ACROSS A RANGE OF STEAP2 EXPRESSING PROSTATE CANCER PDX MODELS
Peter Zanvit, K. McGlinchey, Christine Fazenbaker, Weichuan Luo +4 more
0 citations
Semantic Scholar
The AZD1222 COVID-19 vaccine induces a polyfunctional spike protein-specific Th1 response with a diverse TCR repertoire in humans
Patricia K. Swanson, M. Padilla, W. Hoyland, K. McGlinchey +8 more
immuneACCESS0 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

F. Lee×14
Invite
F. Lee — researcher profile on SciRah
K. Mulgrew×12
Invite
K. Mulgrew — researcher profile on SciRah
Amy Camuso×12
Invite
Amy Camuso — researcher profile on SciRah
S. Hammond×11
Invite
S. Hammond — researcher profile on SciRah

×11

Invite

Krista Fager — researcher profile on SciRah

Invite

C. Flefleh — researcher profile on SciRah

Invite

D. Kan — researcher profile on SciRah

Invite

I. Inigo — researcher profile on SciRah

Invite

Mei-Li Wen — researcher profile on SciRah

Richard A. Smykla×8

Invite

Richard A. Smykla — researcher profile on SciRah

Invite

R. Wild — researcher profile on SciRah

Invite

N. Durham — researcher profile on SciRah